RecruitingNCT07332117
A Pilot Study to Assess Body Mass Composition Measurement Using BIA and Muscle Ultrasound in IPF and PPF Patients on Anti-fibrotic Medications
Sponsor
Royal Brompton & Harefield NHS Foundation Trust
Enrollment
30 participants
Start Date
Sep 9, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
To assess the impact on body mass composition from anti-fibrotic medications used in fibrotic lung disease by using BIA and muscle ultrasound
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- A diagnosis of Idiopathic pulmonary fibrosis or progressive pulmonary fibrosis
- Newly commencing anti-fibrotic medication (either nintedanib or pirfenidone)
- Subject aged \> 18 years
- Able to willingly give consent
Exclusion Criteria9
- Co-morbidities currently requiring enteral feeding
- Weight loss \> 10% in preceding 3-6 months
- Significant musculoskeletal issues that may impact muscle mass
- End of life care (expected \< 6 weeks left to live)
- Previous anti-fibrotic use
- Currently on \> Prednisolone 10mg daily
- Presence of implantable cardioverter defibrillator (ICD) or permanent pacemaker (PPM)
- Heart failure
- Pregnancy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERNo Interventions
No intervention
OTHERNo intervention
No intervention
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07332117
Related Trials
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622372 locations
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT069688457 locations
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535150 locations
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
NCT06329401152 locations
A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
NCT074649121 location